Pfizer starts mid-stage trial of Omicron-targeting vaccine

Reuters

The company did not disclose which subvariant of Omicron the vaccine would be targetting

Leroy Leo, Reuters News

July 27, 2022

PHOTO
FILE PHOTO: FILE PHOTO: People pose with syringe with needle in front of displayed Pfizer logo in this illustration taken, December 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified bivalent COVID-19 vaccine which also targets an Omicron variant.

The company did not disclose which subvariant of Omicron the vaccine would be targetting. (Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)

Reuters

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

ZAWYA NEWSLETTERS

RELATED ARTICLES

ZAWYA NEWSLETTERS

LATEST VIDEO